Efficient intranasal delivery of agomelatine via micellar encapsulation

Announcing a new publication for Acta Materia Medica journal. Agomelatine (AGO) is an antidepressant with limited clinical application due to its low bioavailability caused by poor water solubility, severe hepatic degradation, and poor intracerebral distribution.

Nanotechnology-based strategies constitute a powerful tool by utilizing drug solubility and targeted distribution to improve drug bioavailability in the brain tissues by nose-to-brain drug delivery. In this study AGO was encapsulated within micelles using the commercially available Solutol HS15. As a result, AGO was efficiently loaded on the basis of least micelle size (14.17 ± 0.72 nm) and encapsulation efficiency (96.96%). In vivo and ex vivo experiments showed that micelles provided higher and more sustained brain distribution.

And the results of pharmacokinetic experiments showed that micelles entered the brain region rapidly after intranasal administration and reach its peak within 0.25 h. The behavior of the nanoparticles indicated that the micelles were observed across the olfactory epithelium by examination of nasal mucosal penetration.

This demonstrates that HS15 micelles facilitate penetration of drugs in the olfactory epithelium and provide a system with which to target brain tissues and overcome the problem of inefficient drug delivery of insoluble drugs for central nervous system diseases.

Source:
Journal reference:

Zhang, W., Wan, L., Han, M., Guo, W., Wang, Z., Zhang, X., Liu, X., Wang, J., & Mao, Y. (2024). Nose-to-brain drug delivery by HS15 micelles for brain targeting of insoluble drug. Acta Materia Medica. doi.org/10.15212/amm-2023-0051.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Johns Hopkins researchers discover how epilepsy drug modulates brain activity